For research use only. Not for therapeutic Use.
Selatinib is a a potent dual EGFR/HER-2 inhibitor. Selatinib is also an analog of the quinazoline lapatinib with potential antineoplastic activity. Upon administration, selatinib reversibly blocks phosphorylation of both EGFR and ErbB2, thereby suppressing tumor growth in EGFR/ErbB-2-overexpressing tumor cells. The tyrosine kinases EGFR and ErbB2 have been implicated in the growth of various tumor types.
| Catalog Number | I009424 |
| CAS Number | 1275595-86-2 |
| Synonyms | Selatinib.;N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-(methylsulfinyl)ethyl)amino)methyl)furan-2-yl)quinazolin-4-amine |
| Molecular Formula | C29H26ClFN4O3S |
| Purity | ≥95% |
| Documentation | |
| Target | Protein Tyrosine Kinase/RTK |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4 °C for short term, or -20 °C for long term |
| IUPAC Name | N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfinylethylamino)methyl]furan-2-yl]quinazolin-4-amine |
| InChI | InChI=1S/C29H26ClFN4O3S/c1-39(36)12-11-32-16-23-7-10-27(38-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)37-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35) |
| InChIKey | OAMVGUFHZPRXOM-UHFFFAOYSA-N |
| SMILES | CS(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl |
| Reference | 1:Eur J Med Chem. 2013 Nov;69:833-41. doi: 10.1016/j.ejmech.2013.09.032. Epub 2013 Sep 27. Discovery of a potent dual EGFR/HER-2 inhibitor L-2 (selatinib) for the treatment of cancer.Zhang L,Fan C,Guo Z,Li Y,Zhao S,Yang S,Yang Y,Zhu J,Lin D, PMID: 24121234 DOI: 10.1016/j.ejmech.2013.09.032 </br><span>Abstract:</span> To develop potent dual EGFR/HER-2 inhibitors with improved druggability, a series of new lapatinib analogs were designed and synthesized. Compared with lapatinib, L-2, L-4 and M-6 were more active against BT-474 or NCI-N87 cells. In vivo efficacy studies indicated that L-2 significantly suppressed tumor growth in NCI-N87 (94.8% inhibition) or SK-OV-3 xenograft (85.7% inhibition) without causing significant loss of body weight. And the inhibition rates of lapatinib in the two xenograft models were 89.7% and 78.8%, respectively. Moreover, further studies revealed that the potent in vivo activities of L-2 may be mainly attributed to its superior aqueous solubility and oral bioavailability. In addition, a high-yielding one-pot procedure was developed for the synthesis of lapatinib and its analogs.Copyright © 2013 Elsevier Masson SAS. All rights reserved. |
